

Purpose Statement

Each year, approximately 250,000 patients are diagnosed with prostate cancer in the United States. As the need to identify and treat prostate cancer increases, imaging is a critical tool in its diagnosis, staging and surveillance. **New Vistas in Prostate Cancer Imaging** is designed to help radiologists, oncologists, radiation oncologists and urologists master this continually evolving technology. This activity analyzes the two most promising imaging modalities for prostate cancer. MRI enables identification of clinically significant tumor, and also obviates the need for unnecessary biopsy. Molecular imaging is an emerging tool in the identification of biochemically recurrent cancer. It holds great promise in the staging of prostate cancer at high risk and unfavorable intermediate risk levels. **New Vistas in Prostate Cancer Imaging** reviews essential concepts and multiple cases in both modalities, ensuring the audience a well rounded primer in the visualization, staging and surveillance of this disease.

Target Audience and Objectives

The educational design of this activity addresses the needs of radiologists, oncologists, radiation oncologists and urologists involved in the diagnosis and treatment of prostate cancer.

After completing this activity, the participant should be better able to:

1. Describe state of the art mpMRI and molecular imaging techniques for detection, staging and surveillance of prostate cancer.
2. Discuss the utility of MRI fusion biopsy and in-bore biopsy in the detection of prostate cancer.
3. Develop a successful community based prostate imaging practice based on reliable high quality imaging with PIRADS Lexicon and multidisciplinary communication.
4. Describe novel theranostic therapies for the treatment of prostate cancer.
5. Review new molecular imaging acquisition and interpretation techniques for optimal prostate imaging.
6. Discuss the physiologic basis of PSMA therapy.
7. Discuss how radiogenomics will alter the future landscape of prostate cancer.

Accreditation and Designation

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and Meetings by Mail. Global is accredited by the ACCME to provide continuing medical education for physicians. Global Education Group designates this enduring material for a maximum of 15 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

This enduring material includes 8.25 hours MR, 6 hours PET/Nuclear Medicine, 5.25 hours CT, and 1 hour Ultrasound. Several presentations concern multiple modalities.

All credits for this enduring material are applicable toward Self Assessment CME requirements for Maintenance of Certification (MOC).

There is a fee for this activity.

For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Disclosures of Conflicts of Interest

Global Education Group (Global) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months to Global. All financial relationships reported are identified as relevant and mitigated by Global in advance of delivery of the activity to learners. The content of this activity was vetted by Global to assure objectivity and that the activity is free of commercial bias.

Course Directors: Louis Mazzarelli, MD & Robert Bridwell, MD

Release date: May 1, 2022

Expiration date: April 30, 2025



Meetings By Mail® Presents

New Vistas in Prostate Cancer Imaging

\$595.00

Quantity Discounts Available for Full Staff Coverage

2	3-5	6-9	10+
10% Off!	20% Off!	30% Off!	40% Off!

Visit Meetings-By-Mail.com to see more information, preview videos and place orders, or...

SCAN HERE:



Meetings By Mail®

Meetings-By-Mail.com

Email: Sales@Meetings-By-Mail.com

Twitter: @MeetingsByMail

Phone: (973) 989-0914

611 U.S. Highway 46 West, Suite 401
Hasbrouck Heights, NJ 07604





Meetings By Mail® Presents



**AVAILABLE IN
ONLINE STREAMING
& USB FLASH DRIVE FORMATS**



New Vistas in Prostate Cancer Imaging



**Prostate mpMRI
and PSMA PET
Imaging Primer**

Meetings-By-Mail.com

Jointly provided by
Global Education Group and Meetings By Mail.

Meet CME requirements for MOC

**15 AMA PRA Category I Credits™,™, including 8.25 hours MR, (Presentations Overlap)
6 hours PET/Nuclear Medicine, 5.25 hours CT and 1 hour Ultrasound**



New Vistas in Prostate Cancer Imaging is designed to help radiologists, oncologists, radiation oncologists and urologists master updated visualization techniques. This activity analyzes the two most promising imaging modalities for prostate cancer: multiparametric MRI and PSMA PET/CT. Essential concepts and multiple cases in both modalities are reviewed throughout the course, ensuring the audience a well rounded primer in the latest technology and best strategies to fully examine of this disease. **Worth 15 AMA PRA Category I Credits™,™, which are all applicable for Maintenance of Certification (MOC) requirements.**

This outstanding CME activity includes:


- 28 presentations and panel discussions
- 25 prostate cancer cases analyzing the use of mpMRI and PSMA PET/CT.
- Topics include PI-RADS, targeted biopsy, staging, controversies, Axumin, PET-C11 Choline, community challenges and much more!
- 15 AMA PRA Category I Credits™,™, including 8.25 hours MR, 6 hours PET/Nuclear Medicine, 5.25 hours CT and 1 hour Ultrasound.
- Available in Online Streaming and USB Flash Drive Formats.
- Quantity discounts up to 40% for full staff coverage.

Session 1: Prostate MRI Intro, Protocols and Interpretation

Introduction: Continuing and Emerging Roles for Prostate Imaging Louis Mazzarelli, MD
Mastering Multiparametric MRI Prostate Protocols Angabeen Khan, MD
Anatomy of the Prostate With MRI: Pearls and Pitfalls Louis Mazzarelli, MD
Gamuts of Prostate mpMRI Interpretation. Louis Mazzarelli, MD

Session 2: PIRADSV2.1, MRI-Targeted Biopsy & Extra Prostatic Findings

PIRADSV2.1 Lexicon: Case Based Atlas and Structured Reporting Louis Mazzarelli, MD
Case Conference. Multiple Speakers
Questions and Answers. Multiple Speakers
Extra Prostatic Findings on mpMRI. Louis Mazzarelli, MD
MR/TRUS Fusion Prostate Biopsy Joseph Brito, MD
MR Directed Biopsy: Inbore Biopsy and Developing Inbore Applications Louis Mazzarelli, MD



Session 3: Prostate MRI Staging and Controversies

Prostate MRI for Staging of Prostate Cancer . . . Louis Mazzarelli, MD
Controversies in Prostate Imaging: Biparametric vs mpMRI and Beyond Louis Mazzarelli, MD
Questions and Answers. Multiple Speakers
Case Conference 2 Multiple Speakers

Session 4: Multiparametric MRI Cases


12 mpMRI Cases. Louis Mazzarelli, MD

**NOW
STREAMING
ONLINE**

**Choose Online Streaming
to View On Demand.
USB Flash Drive Format
Also Available!**

Session 5: Prostate Cancer PET/CT Imaging Primer

The Basics of Prostate Cancer Robert Bridwell, MD
PET/CT Applications With FDG and NAF Robert Bridwell, MD
Approved Functional Imaging Robert Bridwell, MD
PSMA PET/CT- Ga68 PET/CT Robert Bridwell, MD
PSMA PET/CT F-18 Pyl and F-18 1007 Robert Bridwell, MD
PSMA Therapy Robert Bridwell, MD



Session 6: Axumin, PET-C11 Choline and Best Practices

The Changing Prostate Panorama: Axumin (18Ffluciclovine) and Its Role in Biochemically Recurrent Prostate Cancer Louis Mazzarelli, MD
PET C-11 Choline Imaging and Other Radiotracers Mark Muscato, MD
Appropriate Patient Selection Robert Bridwell, MD
Maximizing Clinical Performance Case Review . . . Robert Bridwell, MD

Session 7: PSMA PET/CT Cases

13 PSMA PET/CT Cases. Robert Bridwell, MD

Nuclear Medicine, Body, MSK, Oncologic Imaging and More!

Interested in other topics? Visit Meetings-By-Mail.com to see other Radiology CME courses from Penn Radiology, SABI, MECNNMI, Cleveland Clinic and more. Combine courses for maximum savings!

Session 8: Community Challenges and Looking Ahead

Overcoming Challenges to Prostate Imaging Within the Community Center Mark Muscato, MD
Space OAR and Beyond: What the Radiation Oncologists Need To Know Angabeen Khan, MD
Seamless Integration of Fusion Biopsy Within the Community Practice: Case Based Approach Multiple Speakers
Future Horizons for Prostate Imaging: AI, Personalized Care and Prostate Radiogenomics Louis Mazzarelli, MD